Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

Similar articles for PubMed (Select 23401773)

1.

Serum biomarkers identification by mass spectrometry in high-mortality tumors.

Tessitore A, Gaggiano A, Cicciarelli G, Verzella D, Capece D, Fischietti M, Zazzeroni F, Alesse E.

Int J Proteomics. 2013;2013:125858. doi: 10.1155/2013/125858. Epub 2013 Jan 15.

2.

Discovery and application of protein biomarkers for ovarian cancer.

Gagnon A, Ye B.

Curr Opin Obstet Gynecol. 2008 Feb;20(1):9-13. doi: 10.1097/GCO.0b013e3282f226a5. Review.

PMID:
18196999
3.

Lung cancer proteomics: recent advances in biomarker discovery.

Indovina P, Marcelli E, Maranta P, Tarro G.

Int J Proteomics. 2011;2011:726869. doi: 10.1155/2011/726869. Epub 2011 Sep 15.

4.

Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.

Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ, Wei ZJ.

Am J Clin Oncol. 2008 Apr;31(2):133-9. doi: 10.1097/COC.0b013e318145b98b.

PMID:
18391596
5.

Current concepts of tumor markers in bladder cancer.

Droller MJ.

Urol Clin North Am. 2002 Feb;29(1):229-34. Review.

PMID:
12109349
6.

Potential markers for detection and monitoring of ovarian cancer.

Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A.

J Oncol. 2011;2011:475983. doi: 10.1155/2011/475983. Epub 2011 Apr 11.

7.

Application of serum SELDI proteomic patterns in diagnosis of lung cancer.

Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, Chen G, He DC.

BMC Cancer. 2005 Jul 20;5:83.

8.

Advances, challenges, and limitations in serum-proteome-based cancer diagnosis.

Ebert MP, Korc M, Malfertheiner P, Röcken C.

J Proteome Res. 2006 Jan;5(1):19-25. Review.

PMID:
16396491
9.

New cancer biomarkers deriving from NCI early detection research.

Verma M, Srivastava S.

Recent Results Cancer Res. 2003;163:72-84; discussion 264-6. Review.

PMID:
12903844
10.

Cancer diagnosis using proteomic patterns.

Conrads TP, Zhou M, Petricoin EF 3rd, Liotta L, Veenstra TD.

Expert Rev Mol Diagn. 2003 Jul;3(4):411-20. Review.

PMID:
12877381
11.

Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.

Jacot W, Lhermitte L, Dossat N, Pujol JL, Molinari N, Daurès JP, Maudelonde T, Mangé A, Solassol J.

J Thorac Oncol. 2008 Aug;3(8):840-50. doi: 10.1097/JTO.0b013e31817e464a.

PMID:
18670301
12.
13.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

14.

Ovarian cancer biomarkers: a focus on genomic and proteomic findings.

Tinelli A, Vergara D, Martignago R, Leo G, Malvasi A, Tinelli R, Marsigliante S, Maffia M, Lorusso V.

Curr Genomics. 2007 Aug;8(5):335-42. doi: 10.2174/138920207782446142.

15.

Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.

Teunissen CE, Koel-Simmelink MJ, Pham TV, Knol JC, Khalil M, Trentini A, Killestein J, Nielsen J, Vrenken H, Popescu V, Dijkstra CD, Jimenez CR.

Mult Scler. 2011 Jul;17(7):838-50. doi: 10.1177/1352458511399614. Epub 2011 Apr 19.

PMID:
21505015
16.

Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling.

Ehmann M, Felix K, Hartmann D, Schnölzer M, Nees M, Vorderwülbecke S, Bogumil R, Büchler MW, Friess H.

Pancreas. 2007 Mar;34(2):205-14.

PMID:
17312459
17.

Prevention and early detection of ovarian cancer: mission impossible?

Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y.

Recent Results Cancer Res. 2007;174:91-100. Review.

PMID:
17302189
18.

Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.

Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF 3rd.

Proteomics. 2002 Jan;2(1):76-84.

PMID:
11788994
19.

Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients.

El-Aneed A, Banoub J.

Anticancer Res. 2006 Sep-Oct;26(5A):3293-300. Review.

20.

Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.

Wang Q, Li D, Zhang W, Tang B, Li QQ, Li L.

Int J Biol Markers. 2011 Oct-Dec;26(4):262-73. doi: 10.5301/JBM.2011.8616.

PMID:
21928244
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk